Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway.

• Tác giả: Haixin Kou, Ping Liu, Jiarou Wang, Shuo Yang, Yifan Zhang
• Ngôn ngữ: eng
• Thông tin xuất bản: Netherlands : International immunopharmacology , 2025
• Bộ sưu tập: NCBI
• ID: 718381

Tóm tắt

OBJECTIVES: Tanshinone IIA (Tan IIA) exhibits therapeutic potential for atherosclerosis (AS) and hepatic steatosis (HS). The study aims to explore the mechanisms underlying the anti-atherosclerosis and anti-hepatic steatosis effects of Tan IIA. METHODS: The LDLR RESULTS: Tan IIA alleviated LDLR CONCLUSIONS: The study indicated that Tan IIA can alleviate atherosclerosis and hepatic steatosis via down-regulating MAPKs/NF-κB signaling pathway. This provides a potential therapeutic strategy for the co-existing situation of atherosclerosis and hepatic steatosis.